Table 2.
Estimate of key parameters in PASI75, PASI90 and PASI100 final models.
| Essential factor | Parameter | PASI75 | PASI90 | PASI100 | |||
|---|---|---|---|---|---|---|---|
| Estimate | 95%CI | Estimate | 95%CI | Estimate | 95%CI | ||
| Adalimumaba | Emax | 6.42 | (3.83, 9.01) | 6.30 | (3.74, 8.86) | / | / |
| ED50 | 38.61 | (-1.16, 78.38) | 33.60 | (-3.18, 75.72) | / | / | |
| Brodalumaba | Emax | 7.75 | (7.06, 8.44) | 7.14 | (6.61, 7.67) | 6.70 | (6.08, 7.32) |
| ED50 | 147.70 | (117.61, 177.79) | 103.92 | (81.40, 185.32) | 76.19 | (55.38, 97.00) | |
| Bimekizumaba | Emax | 6.10 | (5.67, 6.53) | 5.96 | (5.53, 6.39) | 5.55 | (5.00, 6.10) |
| ED50 | 35.69 | (16.31, 55.07) | 25.75 | (9.88, 35.63) | 24.22 | (6.21, 42.23) | |
| Etanercepta | Emax | 3.74 | (2.88, 4.60) | 4.21 | (2.22, 6.20) | / | / |
| ED50 | 15.40 | (1.19, 29.61) | 18.09 | (-13.50, 49.68) | / | / | |
| Guselkumaba | Emax | 4.52 | (4.27, 4.77) | 4.66 | (4.25, 5.07) | 3.99 | (3.45, 4.53) |
| ED50 | 2.47 | (1.28, 3.66) | 2.46 | (0.93, 3.39) | 2.97 | (0.31, 5.63) | |
| Ixekizumaba | Emax | 5.41 | (5.16, 5.66) | 5.64 | (5.25, 6.03) | 5.34 | (4.70, 5.98) |
| ED50 | 5.50 | (3.68, 7.32) | 3.22 | (1.53, 4.91) | 4.35 | (1.79, 6.91) | |
| Itolizumaba | Emax | 3.48 | (2.05, 4.91) | / | / | / | / |
| ED50 | 12.42 | (-0.46, 25.30) | / | / | / | / | |
| Infliximaba | Emax | 6.17 | (4.62, 7.72) | 5.02 | (2.72, 7.32) | / | / |
| ED50 | 130.76 | (18.91, 242.61) | 93.81 | (-98.95, 286.57) | / | / | |
| Mirikizumaba | Emax | 4.21 | (3.15, 5.27) | 3.96 | (2.73, 5.19) | 5.45 | (1.16, 9.74) |
| ED50 | 7.26 | (1.14, 13.38) | 13.24 | (1.56, 24.92) | 8.41 | (-4.56, 21.38) | |
| Secukinumaba | Emax | 5.92 | (5.51, 6.33) | 6.15 | (5.62, 6.68) | 5.90 | (5.06, 6.74) |
| ED50 | 71.14 | (53.91, 88.37) | 75.31 | (53.93, 96.69) | 82.16 | (42.28, 122.08) | |
| Tildrakizumaba | Emax | 3.42 | (3.17, 3.67) | 4.13 | (3.60, 4.66) | 3.81 | (2.97, 4.65) |
| ED50 | 5.17 | (2.35, 7.99) | 6.98 | (0.20, 13.76) | 5.38 | (-3.02, 13.78) | |
| Ustekinumaba | Emax | 4.38 | (3.91, 4.85) | 4.23 | (3.68, 4.78) | 3.91 | (3.03, 4.79) |
| ED50 | 8.18 | (2.91, 13.45) | 5.07 | (-0.71, 10.85) | -0.21 | (-8.77, 8.35) | |
| Vunakizumaba | Emax | 5.71 | (4.79, 6.63) | 4.70 | (3.58, 5.82) | 4.76 | (2.86, 6.66) |
| ED50 | 44.98 | (22.81, 67.15) | 34.06 | (9.82, 58.30) | 35.78 | (-0.34, 71.90) | |
| Certolizumabb | Emax | 2.69 | (1.26, 4.12) | 3.21 | (1.54, 4.88) | / | / |
| β | 0.12 | (-0.13, 0.37) | 4.5×10-2 | (-0.23, 0.32) | / | / | |
| Risankizumabb | Emax | 3.92 | (-3.66-11.50) | 3.42 | (0.62, 6.22) | 2.46 | (-0.65, 5.57) |
| β | 0.12 | (-1.44, 1.68) | 0.23 | (-0.33, 0.79) | 0.46 | (-0.16, 1.08) | |
| Sonelokimabb | Emax | 2.30 | (0.54, 4.06) | 2.78 | (1.67, 3.89) | 3.49 | (2.04, 4.94) |
| β | 0.60 | (0.17, 1.03) | 0.59 | (0.36, 0.52) | 0.36 | (0.07, 0.65) | |
| Rate constant | KIL-12/23 | 0.29 | (0.24, 0.36) | 0.28 | (0.22, 0.36) | 0.26 | (0.18, 0.38) |
| Covariates | Age (year) | / | / | 0.20 | (-0.19, 0.59) | 0.41 | (-0.13, 0.95) |
| Body weight (kg) | / | / | -0.83 | (-1.18, -0.48) | -0.51 | (-1.07, 0.05) | |
| Disease duration (year) | / | / | / | / | -0.26 | (-0.47, -0.05) | |
| Prior biological therapy (%) | 5.36×10-2 | (1.49×10-2, 9.23×10-2) | 5.50×10-2 | (1.60×10-2, 9.40×10-2) | / | / | |
PASI, Psoriasis Area and Severity Index score; PASI75, PASI90 and PASI100, the proportion of patients achieving ≥75%, 90% and 100% respectively reduction from baseline PASI score; a Emax model with a Emax and a ED50 was used for the dose-response relationship; b log-linear model with a Emax and a β was used for the dose-response relationship.